Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Tarsus Pharmaceuticals (TARS) Receivables - Other (2020 - 2025)

Tarsus Pharmaceuticals has reported Receivables - Other over the past 6 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Receivables - Other at $2.1 million for Q4 2025, up 57.97% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (up 57.97% YoY), and the annual figure for FY2025 was $2.1 million, up 57.97%.
  • Receivables - Other for Q4 2025 was $2.1 million at Tarsus Pharmaceuticals, up from $1.7 million in the prior quarter.
  • Over the last five years, Receivables - Other for TARS hit a ceiling of $7.2 million in Q1 2021 and a floor of $139000.0 in Q3 2021.
  • Median Receivables - Other over the past 5 years was $1.2 million (2024), compared with a mean of $1.6 million.
  • Biggest five-year swings in Receivables - Other: surged 13800.0% in 2021 and later plummeted 95.75% in 2022.
  • Tarsus Pharmaceuticals' Receivables - Other stood at $200000.0 in 2021, then skyrocketed by 1691.0% to $3.6 million in 2022, then plummeted by 69.49% to $1.1 million in 2023, then increased by 18.85% to $1.3 million in 2024, then soared by 57.97% to $2.1 million in 2025.
  • The last three reported values for Receivables - Other were $2.1 million (Q4 2025), $1.7 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.